Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | XDH | P47989 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.46 |
| ▸ | HPGD | P15428 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30740886 | 0.88 | KDM4E (0.57) | KDM4EGAALMNAL3MBTL1XDH | |
| SCHEMBL9475996 | 0.83 | KDM4E (0.48) | KDM4EGAALMNAL3MBTL1XDH | |
| SCHEMBL5924237 | 0.82 | KDM4E (0.63) | KDM4EGAALMNAL3MBTL1XDH | |
| SCHEMBL31520153 | 0.82 | KDM4E (0.50) | KDM4EGAALMNAL3MBTL1XDH | |
| SCHEMBL32669678 | 0.82 | KDM4E (0.50) | KDM4EGAALMNAL3MBTL1XDH | |
| Hydrochloric Acid SCHEMBL9064595 | 0.81 | KDM4E (0.61) | KDM4EGAALMNAL3MBTL1XDH | |
| SCHEMBL10323175 | 0.81 | GAA (0.49) | KDM4EGAALMNAL3MBTL1XDH | |
| SCHEMBL18031473 | 0.81 | GAA (0.49) | KDM4EGAALMNAL3MBTL1XDH | |
| SCHEMBL10322828 | 0.81 | KDM4E (0.49) | KDM4EGAALMNAL3MBTL1XDH | |
| SCHEMBL31520159 | 0.81 | KDM4E (0.53) | KDM4EGAALMNAL3MBTL1XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223286-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO.,LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| CN-113365995-B | Immunomodulators, compositions and methods thereof | 贝达药业股份有限公司 | 2025-03-04 | — | — | CN | disclosed |
| US-12187713-B2 | Immunomodulators, compositions and methods thereof | BETTA PHARMACEUTICALS CO., LTD (CN) | 2025-01-07 | — | — | US | disclosed |
| CN-115884972-A | Immunomodulator, composition and application thereof | 贝达药业股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20220098183-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO LTD (CN) | 2022-03-31 | — | — | US | disclosed |
| WO-2022022600-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022022600-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2022-02-03 | — | — | WO | disclosed |
| EP-3917927-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2021-12-08 | — | — | EP | disclosed |
| CN-113365995-A | Immunomodulator, composition and method thereof | 贝达药业股份有限公司 | 2021-09-07 | — | — | CN | disclosed |
| WO-2020156323-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020156323-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223286-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | IL2, IL5, TSLP | KDM4E 3786/4885GAA 1943/4885LMNA 4673/4885 |
| US-20220098183-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | IL2, TSLP, CD74 | KDM4E 4123/4885GAA 2512/4885LMNA 4694/4885 |
| US-12187713-B2 | Immunomodulators, compositions and methods thereof | IL2, TSLP, CD74 | KDM4E 4123/4885GAA 2512/4885LMNA 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.